ABL1 and acute lymphoblastic leukemia: Dasatinib is active in children and adults with Ph+ ALL harboring a BCR::ABL1 fusion and is now commonly used in combination with standard chemotherapy to treat children with Ph+ ALL (Shen et al., 2020).